Angiodroid

About

Angiodroid SpA is an Italian medical technology company founded in 2013, specializing in innovative solutions for vascular and interventional procedures. Transitioning to a Joint Stock Company in 2023, Angiodroid focuses on enhancing patient quality of life through a blend of clinical and engineering expertise. The company operates in four key medical specialties: Vascular Surgery, Interventional Radiology, Interventional Cardiology, and Interventional Angiology. Its flagship product, the CO₂ Injector, is the first automated carbon dioxide injector for peripheral angiography, designed to reduce the risk of contrast-induced acute kidney injury. Angiodroid also offers disposables like the Single Use Adaptor and Procedural Kit. With a structured organization, Angiodroid emphasizes innovation, passion, and quality across its departments, including R&D, Clinical Development, Sales, and Marketing. The company has secured significant investments to expand its international presence and is developing additional products like Angiopulse. Angiodroid engages with customers through free product demonstrations and educational webinars featuring medical professionals.